Latest Updates
Read the latest news that impacts the oncology community.
There’s now a chance for bipartisan health care policies, but partisan tensions are running high
WASHINGTON — Republicans’ first major policy bill this year was a partisan affair: They cut Medicaid funding by some $1 trillion to help fund tax cuts prized by President Trump.
Read MoreThe megabill’s Medicaid cuts shocked hospitals, but they may never happen
Hospitals lost big in President Donald Trump’s megabill, but they still have plenty of time to fight back.
Read MoreCrunch time for Congress on health issues after tax bill passage
While President Donald Trump’s “One Big Beautiful Bill” did a whole lot the healthcare sector opposes, it also failed to deal with a plethora of more mundane health legislation lawmakers must finalize as soon as this fall.
Read MoreRural hospitals eye service expansions to weather federal cuts
Rural hospitals are hopeful they can add rather than reduce services to help soften the blow from looming Medicaid and Medicare cuts.
Read MoreWho Decides if a Cancer Drug Is “Worth It”? Former FDA Reviewer Points to Missing Input
When Erika Newell’s breast cancer recurred, she found herself doing something that she had rarely done before her diagnosis: carefully tracking news about science and drug approvals.
Read MoreCOA Applauds Bipartisan Congressional Legislation Targeting PBM Abuses
The Community Oncology Alliance (COA) strongly supports the “PBM Reform Act,” a new reform package introduced today by Rep. Buddy Carter (R-GA-1) and a bipartisan group of lawmakers that takes direct aim at the entrenched practices of pharmacy benefit managers (PBMs) driving up drug costs and undermining care for patients with cancer and other serious conditions.
Read MoreMany 340B Disproportionate Share Hospitals Fail to Reinvest in Patient Care
WASHINGTON--(BUSINESS WIRE)--A new analysis of 340B hospital data found that the number of Disproportionate Share Hospitals (DSHs) participating in the 340B Drug Pricing Program1 has surged more than sixfold, rising 565% from 2004 to 2023, with little evidence of commensurate growth in benefit to vulnerable populations. Yet, following 340B enrollment, DSHs’ financial investments, including stocks, bonds and other financial instruments, soared.
Read MoreOpinion | Protect Wisconsin cancer patients from drug profiteers
As an oncologist in Wisconsin, I’ve seen the toll that high drug costs take on cancer patients. Even with insurance, many struggle to afford life-saving medications.
Read More200% drug tariffs loom as Trump pushes reshoring of pharma manufacturing
The Trump administration is threatening to impose large tariffs on drugs imported into the United States, although they wouldn’t take effect for at least a year.
Read MoreHow Trump's One Big Beautiful Bill Act will increase employer healthcare costs
Employers should expect to see hikes to their healthcare costs as a result of upcoming cuts to Medicaid outlined in the Trump administration's One Big Beautiful Bill, passed into law at the start of July. Preparing for the ripple effects now can help benefit leaders reduce the connected negative impact on their workforce.
Read More